Table 3.
Clinical trials in vaccines targeting non-viral antigens.
| Identifier and Reference | Vaccine ± Other Therapy | Phase | Type of Vaccine | N | Target Antigens | Population | Primary Endpoint | Status |
|---|---|---|---|---|---|---|---|---|
|
NCT00404339 Ref. [93] |
Peptide pulsed DCs |
I | DC | 16 | p53 | HLA-A2.1-positive patients with treated HNSCC | Safety | Completed |
| UMIN000000976 Ref. [94] |
Survivin-2B vaccine |
I | Peptide | 10 | Survivin-2B | 10 HLA-A24-positive patients with advanced or recurrent oral cancer | Safety | Completed |
|
NCT00050388 Ref. [95] |
Allovectin-7 | I/II | DNA | 69 | Restore HLA-B7/β2 | Persistent or recurrent HNSCC after (chemo)radiotherapy | Safety | Completed |
| NA Ref. [99] |
Peptide vaccine | II | Peptide | 55 | LY6K, CDCA1 and IMP3 | HLA-A24-positive patients with advanced HNSCC | Overall survival | Completed |
|
NCT02999646 [101] |
MVX-ONCO-1 | II | Personalized | ±41 | Autologous tumor cells | Advanced HNSCC | Overall survival | Recruiting |
|
NCT01998542 Ref. [102] |
AlloVax | II | Personalized | 10 | Chaperone-enriched tumor cell lysate | Advanced chemo-resistant HNSCC | Efficacy | Completed |
|
NCT03946358 NA |
UCPVax | II | Peptide | ±47 | Telomerase | HPV+ cancers (head and neck, anal, and cervical cancers) | Efficacy | Recruiting |
|
NCT03552718 NA |
YE-NEO-001 | I | Personalized | ±16 | NA | Solid cancers in curative post-treatment surveillance period | Safety | Unknown |
|
NCT03548467 NA |
CB10.NEO + Bempegaldek-leukin | I/II | Personalized | ±65 | NA | Locally advanced or metastatic solid tumors | Safety | Recruiting |
|
NCT00019331 NA |
Ras vaccine | II | Peptide | NA | Ras | Metastatic solid tumors | IR, Efficacy, and Safety | Completed |
|
NCT00021424 NA |
TRICOM vaccine | I | Live (Fowlpox virus) | Max 20 | Expression of B7-1, ICAM-1, and LFA-3 | Advanced SCC of the oral cavity or oropharynx or nodal or dermal metastases | DLT | Completed |
|
NCT02544880 Ref. [97] |
MUC1 vaccine + Tadalafil | I/II | Peptide | 16 | MUC1 | Resectable and recurrent or second primary HNSCC | I: Safety II: IR |
Completed |
|
NCT04247282 NA |
M7823 ± TriAd vaccine * ± N-803 |
I/II | Live (Adenovirus) | ±40 | Brachyury, Mucin-1, and CEA | p16-negative resectable HNSCC | Efficacy | Suspended |
|
NCT04266730 NA |
PANDA-VAC | I | Personalized peptide | ±6 | NA | Advanced lung cancers or HNSCC under Pembrolizumab | Safety | Not yet recruiting |
|
NCT03689192 NA |
ARG1 vaccine | I | Peptide | ±10 | Arginase-1 | Metastatic solid tumors | Safety | Recruiting |
|
NCT03311334 NA |
DSP-7888 + ICI | Ib/II | Peptide | ±84 | WT1 | Advanced solid tumors | I: Safety II: Efficacy |
Recruiting |
|
NCT04445064 NA |
IO102 | II | Peptide | 18 | IDO | Curable HNSCC | Biological activity | Recruiting |
|
NCT04470024 NA |
DPV-001 + delayed anti-PD1 ± anti-GITR | Ib | Autophagosome-enriched vaccine | 56 | NA | R/M HNSCC | Safety | Recruiting |
|
NCT05075122 NA |
UV1 vaccine + Pembrolizumab + Sargramostism | II | Peptide | 75 | Telomerase | R/M HNSCC with CPS ≥1 | Efficacy | Recruiting |
DLT: dose-limiting toxicity; HSV: herpes simplex virus; ICI: immune checkpoint inhibitor; IDO: indoleamine-2,3-dioxygenase; IR: immune response; NA: not available; HNSCC: head and neck squamous cell carcinoma. * TriAd vaccine: ETBX-051 (adenoviral brachyury vaccine) + ETBX-061 (adenoviral Mucin-1 (MUC1) vaccine) + ETBX-011 (adenoviral carcinoembryonic antigen (CEA) vaccine).